What is XENLETA?
XENLETA is a systemic pleuromutilin antibacterial agent that inhibits bacterial protein synthesis. It acts by binding to the peptidyl transferase center, or PTC, on the bacterial ribosome in such a way that it interferes with the interaction of protein production at two key sites known as the “A” site and the “P” site. This results in the inhibition of bacterial proteins and the cessation of bacterial growth.
The product is made available in two formulations – 150mg injection for intravenous administration and 600mg oral tablets.
XENLETA was approved by the U.S. Food and Drug Administration in August 2019.
In July 2020, the European Commission (EC) approved the marketing authorization application for XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for initial treatment or when these agents have failed.